Applications to the Fiscal Year 2015 (FY15) Reconstructive Transplant Research (RTR) program) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. This Program Announcement/Funding Opportunity and subsequent awards will be managed and executed by the Congressionally Directed Medical Research Programs (CDMRP) with strategic oversight from Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). To meet the intent of the FY15 RTR award mechanisms, applicants must address one or more of the Focus Areas listed below. â€˘ Immune system regulation â€˘ Improved access to reconstructive transplantation â€˘ Reconstructive transplantation rehabilitation â€˘ Graft surveillance â€“ Clinical monitoring â€˘ Psychosocial issues associated with VCA. The RTR Translational Research Award (RTR TRA) mechanism is being offered for the first time in FY15. A synopsis of all FY15 RTR Program Announcements/Funding Opportunities is available at http://cdmrp.army.mil/funding/pdf/15rtrpreftable.pdf The intent of the FY15 RTR TRA mechanism is to support the development of data and model systems to complete the Food and Drug Administration (FDA) regulatory review process and position the product for a clinical trial. Applications must include preliminary and/or published data that is relevant to RTR and the proposed research project. Observations that drive a research idea may be derived from many sources, such as a laboratory discovery, population-based studies, or a clinicianâ€™s firsthand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into clinical application, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve reciprocal flow of ideas between basic and clinical science. Collaborations between laboratory scientists and clinicians are encouraged.